An interventional study of Closed-loop FiO2 controller and Conventional in Acute Hypoxemic Respiratory Failure, Acute Hypercapnic Respiratory Failure and Respiratory Depression, sponsored by Başakşehir Çam & Sakura City Hospital. Recruiting at 2 sites in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-28.
Sponsored by Başakşehir Çam & Sakura City Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Respiratory Insufficiency with a site in Turkey — 10 open to participants now, 10 under way, none of them phase 3. Respiratory Insufficiency · Turkey.
Among the 51 studies in Respiratory Insufficiency with a site in Turkey, this one is the 19th largest by planned enrollment of the 26 interventional ones that give a count, is one of 8 that started in 2024, is one of 24 with no phase, and was the 33rd registered.
1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.
Browse Respiratory Insufficiency studies →10 of the 51 studies in Respiratory Insufficiency with a site in Turkey are open now. Recruiting first, the newest first:
Kocaeli City Hospital · Sites in Turkey
Ages 18+
Istanbul Saglik Bilimleri University · Sites in Turkey
Ages 18+
Medipol University · Sites in Turkey, Chile, Egypt and 3 more countries
Ages 18–89
Lokman Hekim Üniversitesi · Sites in Turkey
Ages 5–15 · Healthy volunteers
Nilgün Erdoğan · Sites in Turkey
Ages 18+ · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 60 across 861 interventional studies indexed under Respiratory Insufficiency.
Median enrollment 90 across the 26 interventional studies, 108 across the 25 observational. Of the 38 that completed or were terminated, 3 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 51 have an industry lead sponsor. The 10 most frequent:
Başakşehir Çam & Sakura City Hospital is the lead sponsor of 110 studies on the registry; 35 are open to participants now.
Başakşehir Çam & Sakura City Hospital has 1 study filed under Respiratory Insufficiency — fewer than ten, so there is no comparison to draw.
4 of the studies in Respiratory Insufficiency with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07098611Medipol UniversityA New Tool for Extubation Readiness in Mechanically Ventilated Patients: Readiness for EXtubation Score | 2026-12-30 |
| NCT07805603Medipol UniversityHERMES: Quality and Safety of Advanced Respiratory Support During Patient Transport | 2027-06-01 |
| NCT07610122Istanbul Saglik Bilimleri UniversityValidation of the Turkish Version of the S3-NIV Questionnaire | 2027-06-30 |
| NCT07909226Kocaeli City HospitalLactate/Albumin Ratio and Mortality in Respiratory Failure | 2027-11-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 51 studies in Respiratory Insufficiency with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
High flow nasal oxygen therapy (HFNO) is an established modality in the supportive treatment of patients suffering from acute hypoxemic respiratory failure. The high humidified gas flow supports patient's work of breathing, reduces dead space ventilation, and improves functional residual capacity while using an unobtrusive patient's face interface [Mauri et al, 2017; Möller et al, 2017].
As hyperoxia is considered not desirable [Barbateskovic et al, 2019] during any oxygen therapy, the inspired O2 concentration is usually adapted to a pre-set SpO2 target-range of 92-96% in patients without hypercapnia risk, and of 88-92% if a risk of hypercapnia is present [O'Driscoll et al, 2017; Beasley et al, 2015]. In most institutions, the standard of care is to manually adapt the FiO2, although patients frequently have a SpO2 value outside the target range.
A new closed loop oxygen controller designed for HFNO was recently developed (Hamilton Medical, Bonaduz, Switzerland). The clinician sets SpO2 targets, and the software option adjusts FiO2 to keep SpO2 within the target ranges. The software option offers some alarms on low and high SpO2 and high FiO2. Given the capability, on the one hand, to quickly increase FiO2 in patients developing sudden and profound hypoxia, and, on the other hand, of automatically preventing hyperoxia in patients improving their oxygenation, such a system could be particularly useful in patients treated with HFNO.
A short-term (4 hours vs 4 hours) crossover study indicated that this technique improves the time spent within SpO2 pre-defined target for ICU patients receiving high-flow nasal oxygen therapy [Roca et al, 2022]. Due to its simplicity, HFNO is increasingly used outside the ICU during transport and in the Emergency Room (ER). This environment poses specific challenges, as patients may deteriorate very quickly and depending on patient's flow, healthcare providers can easily be overwhelmed. We thus propose to evaluate closed loop controlled HFNO in ER patients.
The hypothesis of the study is that closed loop oxygen control increases the time spent within clinically targeted SpO2 ranges and decreases the time spent outside clinical target SpO2 ranges as compared to manual oxygen control in ER patients treated with HFNO.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who fulfil any of the following exclusion criteria are not eligible for study participation:
Post enrollment exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Six hours period where the fraction of inspired oxygen (FiO2) delivered will be automatically titrated based on SpO2 values obtained from the patient.
Device: Closed-loop FiO2 controller
Six hours period where the fraction of inspired oxygen (FiO2) delivered will be manually titrated by clinician based on SpO2 values obtained from the patient.
Device: Conventional
Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
Six hours period where the fraction of inspired oxygen (FiO2) delivered will be manually titrated by clinician based on SpO2 values obtained from the patient.
Percentage of time spent in optimal SpO2 range
The optimal SpO2 range will be defined according to the SpO2 targets determined by the clinician.
Time frame: 6 hours
Percentage of time with SpO2 signal available
Time with SpO2 signal available
Time frame: 6 hours
Percentage of time with SpO2 below target range
SpO2 values below the optimal range
Time frame: 6 hours
Percentage of time with SpO2 above target range
SpO2 values above the optimal range
Time frame: 6 hours
Percentage of time with SpO2 outside optimal range
SpO2 values outside the optimal range
Time frame: 6 hours
Percentage of time with with FiO2 below 40%
Duration of time with FiO2 \< 40 %
Time frame: 6 hours
Percentage of time with with FiO2 above 60%
Duration of time with FiO2 \> 60 %
Time frame: 6 hours
Percentage of time with with FiO2 = 100%
Duration of time with FiO2 = 60 %
Time frame: 6 hours
Mean SpO2/FiO2
Mean SpO2/FiO2
Time frame: 6 hours
Number of events with SpO2 below of target range (duration >10 s)
Frequency of events with SpO2 below of target range (duration \>10 s)
Time frame: 6 hours
Number of events with SpO2 below of target range (duration >60 s)
Frequency of events with SpO2 below of target range (duration \>60 s)
Time frame: 6 hours
Number of events with SpO2 below the predefined low SpO2 emergency limit
Frequency of events with SpO2 below of the predefined low SpO2 emergency limit
Time frame: 6 hours
Number of events with SpO2 above the predefined low SpO2 emergency limit
Frequency of events with SpO2 above of the predefined low SpO2 emergency limit
Time frame: 6 hours
Total oxygen use
Amount of additional oxygen use
Time frame: 6 hours
Started Mar 2024 (actual). Primary completion is estimated for Dec 2025, 21 months after the start.
Of 360 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 21 months is below that.
Counting every sponsor, half of 376 studies reached it within 24 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Başakşehir Çam & Sakura City Hospital →